Dr. Reddy's inks pact with Singapore firm to commercialise Trastuzumab biosimilar in select countries

Prestige BioPharma Ltd, a Singapore-based firm and Dr. Reddys Laboratories Ltd., on Thursday announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of the formers proposed Trastuzumab biosimilar in select countries in Latin America and Southeast Asia. Prestige BioPharmas Trastuzumab HD201 is a proposed biosimilar to Roches Herceptin and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer, a regulatory filing from the Indian drugmaker said. Trastuzumab targets human epidermal growth factor 2 HER2.


PTI | Hyderabad | Updated: 09-12-2021 13:34 IST | Created: 09-12-2021 13:32 IST
Dr. Reddy's inks pact with Singapore firm to commercialise Trastuzumab biosimilar in select countries
Representative Image
  • Country:
  • India

Prestige BioPharma Ltd, a Singapore-based firm, and Dr. Reddy's Laboratories Ltd., on Thursday, announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of the former's proposed Trastuzumab biosimilar in select countries in Latin America and Southeast Asia.

Prestige BioPharma's Trastuzumab (HD201) is a proposed biosimilar to Roche's Herceptin and can be prescribed for the treatment of HER2 positive breast and metastatic gastric cancer, a regulatory filing from the Indian drugmaker said.

Trastuzumab targets human epidermal growth factor 2 (HER2). In some types of cancer cells, HER2 is overexpressed and stimulates the growth of the cancer cells. Trastuzumab works by selectively binding to HER2, thereby stopping the growth of these cancer cells, it said.

Under the partnership, Prestige BioPharma will be responsible for sustainable commercial supply of HD201 from its manufacturing facilities in Osong, South Korea, while Dr. Reddy's will be responsible for local registrations, marketing, and sales in the licensed territories.

Lisa S Park, CEO of Prestige BioPharma, commented: ''We are delighted to establish a partnership with Dr. Reddy's for key Latin American and Southeast Asian markets. Dr. Reddy is the ideal partner to commercialize our lead biosimilar in these territories. With this collaboration, we look forward to further strengthening the value of our biosimilar programs in global markets.'' M V Ramana, CEO Branded Markets (India & Emerging Markets), Dr. Reddy's, said: ''In keeping with our purpose of accelerating access to affordable and innovative medicines, we are happy to bring this life-saving drug to patients in need. Our partnership with Prestige BioPharma will help us combine their established expertise in the area of biosimilars with our commercial strengths and growth ambition in these markets. This is in line with our stated intention to create a portfolio of oncology products and expand our biosimilar offerings in Emerging Markets.'' Meanwhile in a separate release, Dr. Reddy's announced the launch of Valsartan Tablets, USP, a therapeutic equivalent generic version of Diovan (valsartan) Tablets approved by the US Food and Drug Administration (USFDA) in the US market. The drug is used to treat high blood pressure. Dr. Reddy's Valsartan Tablets, USP are available in 40 mg in bottle count size of 30, and 80 mg, 160 mg, and 320 mg tablets in bottle count sizes of 90, it said.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback